Group items tagged

Healthcare has a strong relationship with technology. The modern structure of hospitals and medical facilities cannot function without the progress of technology. It is important to acknowledge the impact of technology to ensure that priority is given to the constant maintenance of innovation. Here are a few ways to understand how healthcare and technology operate together. TECHNOLOGICAL INNOVATIONS KEEPING UP WITH MEDICAL DEMANDS Healthcare has become increasingly dependent upon technology throughout the years. There is an almost infinite amount of equipment and machinery that is used on a day-to-day basis to help facilitate the care of patients. One aspect that needs to be acknowledged is the prevalence of smart technology within the hospital and healthcare spaces. Technology is being innovated, and it is only a matter of time until hospitals see such advancements be applied more often, as funding increases alongside the development of new machinery and equipment. These include the inclusion of artificial intelligence in order to assist and supplement healthcare professionals to do a better and more efficient job, providing better care for patients. Of course, such technology will need to follow trends of other industries first to ensure its safe use and application when dealing with patients.

In recent years, the healthcare sector has seen a significant transformation driven by the rapid advancement of technology. From improved patient care to streamlined administrative processes, technology has become an indispensable part of modern healthcare. As medical facilities worldwide embrace these innovations, it's essential to understand why the sector leans so heavily on advanced technological solutions. Below are seven key reasons illustrating the crucial role of technology in healthcare. Enhanced Radiology Workflows Advancements in technology have revolutionized radiology workflows, making the process more efficient and accurate. Digital imaging technologies, such as PACS (Picture Archiving and Communication Systems) and RIS (Radiology Information Systems), allow for the seamless storage, retrieval, and sharing of medical images. The specialists AbbaDox say that this reduces the time needed to diagnose and treat patients, significantly improving the overall efficiency of radiology departments. Additionally, AI-powered tools can assist radiologists by highlighting potential areas of concern within images, ensuring that abnormalities are not overlooked. These improvements contribute to faster, more accurate diagnoses and better patient outcomes.

As we take look back over the past year and reflect on what we have achieved, it's also important that we look ahead to new challenges and opportunities that may arise in 2023. We have seen remarkable innovation across the industry in 2022, from big break throughs in treatment and improvements to patient outcomes, to how the industry is working with big data and technology. But it's fair to say that these achievements came paired with just as many challenges including a continued talent shortage, hangovers from the pandemic, increasing pressures to innovate and ongoing macroeconomic challenges. As we head into 2023, I expect these existing challenges to continue alongside new ones, but I also anticipate more opportunities to present themselves. At Pharamanovia, we predict that the key trends set to catalyse the pharmaceutical and healthcare industries in 2023 include break through innovations, technology, big data, sustainability, ongoing policy changes and a shift in investment due to inflation. Utilising big data and tech Technology has been recognised as one of the industry's biggest tools for many years, and I don't expect to see the pace of how we use technology in healthcare and pharma to slow down any time soon. In 2023, I expect that we will see further automation in the way we work, with an increase in digital engagement and healthcare providers leveraging remote access further.

AI in medical devices enhances clinical technology by enabling real-time signal analysis and timely responses. These devices assist care teams to improve outcomes and adapt as healthcare evolves. This blog will present an overview, key applications, challenges, and future trends, and how this technology is revolutionizing the healthcare sector.

AI in medical devices enhances diagnostics, therapy, and monitoring. Discover the impact of AI solutions for healthcare in medical device software.

Accord Healthcare is set to expand its manufacturing and production capabilities for high-quality medicines at its Fawdon plant in Newcastle upon Tyne, England, following a new multi-million-pound investment deal with the government. Chancellor of the Exchequer Rachel Reeves launched the new Life Sciences Innovative Manufacturing Fund (LSIMF) and announced the unlocking of a joint £50 million investment deal during her visit to the Fawdon plant on 1 November. Unveiled as part of a new budget, the LSIMF will distribute up to £ 520 million in capital grants aimed at drug and medical technology production. Accord stated that it will allocate the funding towards developing new product lines, including a novel prostate cancer drug and two autoimmune injectables for treating rheumatoid arthritis and gastroenterology indications, as well as expanding its medicines for adjunctive therapy in cancer. With this investment, Accord also plans to create over 50 new skilled jobs to "safeguard the facility's long-term future." Paul Tredwell, executive vice president of Accord Healthcare EMENA, welcomed the announcement and described it as positive news for the medicines manufacturing industry across the UK.

The 8th Pharmacy Business Conference, organised by Pharmacy Business, unfolded a dynamic narrative around the theme of 'Pharmacy of Tomorrow', highlighting the trajectory of innovation, adaptation, and the evolving landscape of pharmaceutical services. Attended by over 200 pharmacy owners, industry leaders, and stakeholders, the conference served as a medium for robust discussions and the exchange of valuable insights regarding the future of community pharmacy. Amidst the persistent challenges posed by an underfunded reimbursement system and negotiations with governmental bodies and the NHS for the new community pharmacy contractual framework 2024/25, the conference pivoted towards investing in staff, adapting to change by investing in new technology, and optimising commissioning as pivotal strategies. "Pharmacy professionals are playing increasingly important clinical roles in both primary and secondary care," shared David Webb, Chief Pharmaceutical Officer (CPO), NHS in a video message. He highlighted the NHS's commitment to empowering community pharmacy, with plans to expand services and deprescribe to align with the NHS's focus on preventive healthcare.

The UK pharmaceutical industry experienced a substantial increase in public trust and favourability during the Covid-19 pandemic, according to a new poll. This trend appears to be persisting with the study showing a generally favourable view of the sector. The recent survey, conducted by Ipsos and commissioned by Association of the British Pharmaceutical Industry (ABPI), represents the third instalment in a series that began in 2021. This ongoing study targets members of the public, healthcare professionals, and parliamentarians. The study once again underscored a favourable perception of the sector with 67 per cent of respondents recognising that the pharmaceutical industry produces safe and effective medicines using cutting-edge technologies. Moreover, a majority agrees that it is a highly innovative field. Seven out of 10 people also trust the sector's readiness to address future pandemics, even as media attention on pharmaceutical companies returns to pre-pandemic levels. However, concerns arise regarding limitations in accessing new medicines due to cost pressures.

Take Home: UMass Medical School and WPI have developed an app that can detect atrial fibrillation.  This moves connected and mobile health closer to reality.  The really important development with this approach might allow us to treat patients who have AF intermittently (paroxysmal) differently than we currently do.  Because we are worried about stroke, patients now get blood thinners all the time because we are concerned that they will have recurrences without knowing about it.  With this technology, in the future, we might see validation of a strategy that allows use of blood thinners when patients are in AF only, sometimes called a pill in the pocket.

The Royal Pharmaceutical Society (RPS) has published a new policy outlining how artificial intelligence (AI) can be used to support pharmacy practice and improve patient care. The content has been developed in consultation with RPS members, Expert Advisory Group members, Board members, multi-professional experts in digital technology and AI, and external stakeholders including the General Pharmaceutical Council (GPhC). The policy highlights the opportunities, challenges and potential applications of AI within pharmacy now and in the future. RPS President, Professor Claire Anderson, acknowledges that AI technologies have the potential to transform pharmacy practice, noting that "there are some great examples where it's already in use." "We must optimise the opportunities that these advancing technologies can bring to enhance patient access to care, improve patient experience, support clinical decision making and improve the safety and efficiency of the medicines supply chain. "Our policy provides a framework to ensure AI is harnessed safely and effectively to support pharmacists and patients," she adds.

Transitioning from analogue to digital is one of three major "shifts" the government has deemed essential for the future of the NHS. These shifts, with the other two being the moving from hospital to community care and from sickness to prevention, will also form the foundation of the 10-Year Health Plan. The question is: are the public ready to embrace this digital transformation, which would involve sharing their health data for the development of artificial intelligence (AI) systems within the NHS? Results from a UK-wide poll show that the majority of people (75 per cent) are willing to share some of their health data for AI development. The survey commissioned by the Health Foundation included more than 7,000 members of the public (aged 16 years and older). Nearly 60 per cent expressed willingness to share information about their eye health, with 58 per cent open to sharing details about the medications they are taking, and 57 per cent willing to disclose any long-term illnesses they live with.

The Market Research on Wound Debridement, By Considering useful aspects like; Material, Product, Application, End User (Hospital, ASCs) - Global Future Forecast till 2023, published by MarketsandMarkets™, the report studies the global Wound Debridement market over the forecast period of 2017 to 2023. The market is projected to reach USD 1,041.0 Million by 2023 at a CAGR of 8.2%.